Virtus ETF Advisers LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Virtus ETF Advisers LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$20.26 - $31.91 $5,814 - $9,158	-287 Reduced 9.02%	2,895 $63,000
Q2 2023 Aug 14, 2023	SELL	$23.9 - $35.38 $13,814 - $20,449	-578 Reduced 15.37%	3,182 $101,000
Q1 2023 May 15, 2023	SELL	$22.82 - $35.32 $33,111 - $51,249	-1,451 Reduced 27.84%	3,760 $91,000
Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $23,220 - $29,275	916 Added 21.33%	5,211 $164,000
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $918 - $1,491	36 Added 0.85%	4,295 $121,000
Q2 2022 Aug 12, 2022	SELL	$20.62 - $37.15 $19,733 - $35,552	-957 Reduced 18.35%	4,259 $113,000
Q1 2022 May 16, 2022	SELL	$23.5 - $35.38 $7,261 - $10,932	-309 Reduced 5.59%	5,216 $183,000
Q4 2021 Feb 14, 2022	SELL	$29.21 - $44.64 $296,247 - $452,738	-10,142 Reduced 64.73%	5,525 $179,000
Q3 2021 Nov 15, 2021	SELL	$21.26 - $38.85 $17,369 - $31,740	-817 Reduced 4.96%	15,667 $462,000
Q2 2021 Aug 10, 2021	BUY	$12.56 - $29.69 $207,039 - $489,409	16,484 New	16,484 $422,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.